title: Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
abstract: The serine protease inhibitor (serpin) C1 inhibitor inactivates enzymes involved in the regulation of vascular permeability. A patient from the Ma family with the genetic disorder hereditary angioedema inherited a dysfunctional C1 inhibitor allele. Relative to normal plasma, the patients's plasma contained an additional C1 inhibitor immunoreactive band, which comigrated with normal C1 inhibitor cleaved by plasma kallikrein, C1s, or factor XIIa. C1 inhibitor Ma did not react with a monoclonal antibody to a neoepitope that is present in complexed and cleaved normal C1 inhibitor, suggesting conformational differences between cleaved normal C1- inhibitor and cleaved C1 inhibitor Ma. Molecular cloning and sequencing of exon 8 of the C1 inhibitor Ma allele revealed a single C to A mutation, changing alanine 434 to glutamic acid. Ala 434 of C1 inhibitor aligns with the P12 residue of the prototypical serpin alpha 1-antitrypsin. The P12 amino acid of all inhibitory serpins is alanine, and it is present in a highly conserved region on the amino-terminal side of the serpin-reactive center loop. Whereas normal C1 inhibitor expressed by transfected COS-1 cells formed complexes with and was cleaved by kallikrein, fXIIa, and C1s, COS-1-expressed Ala434---Glu C1 inhibitor was cleaved by these enzymes but did not form complexes with them. These results, together with evidence from other studies, suggest that serpin protease inhibitor activity is the result of protein conformational change that occurs when the P12 region of a serpin moves from a surface location, on the reactive site loop of the native molecule, to an internal location within sheet A of the complexed inhibitor.
authors.affiliation: Department of Microbiology/Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
authors.forename: K
authors.initials: K
authors.lastname: Skriver
authors.forename: W R
authors.initials: WR
authors.lastname: Wikoff
authors.forename: P A
authors.initials: PA
authors.lastname: Patston
authors.forename: F
authors.initials: F
authors.lastname: Tausk
authors.forename: M
authors.initials: M
authors.lastname: Schapira
authors.forename: A P
authors.initials: AP
authors.lastname: Kaplan
authors.forename: S C
authors.initials: SC
authors.lastname: Bock
mesh_terms: D000595:Amino Acid Sequence; D000799:Angioedema / Q000201:enzymology*; D000911:Antibodies, Monoclonal; D000990:Antithrombin III / Q000737:chemistry; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency* / Q000378:metabolism; D003173:Complement C1s / Q000378:metabolism; D005796:Genes; D006801:Humans; D007610:Kallikreins / Q000494:pharmacology; D008969:Molecular Sequence Data; D009154:Mutation; D010449:Peptide Mapping; D011485:Protein Binding; D015843:Serpins / Q000378:metabolism*; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal; D003174:Complement C1 Inactivator Proteins; D015843:Serpins; D000990:Antithrombin III; D007610:Kallikreins; D003173:Complement C1s